Lisa B Nachtigall1, Niki Karavitaki2, Katja Kiseljak-Vassiliades3, Luma Ghalib4, Hidenori Fukuoka5, Luis V Syro6, Daniel Kelly7, Maria Fleseriu8. 1. Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School Boston, Boston, MA, USA. 2. Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University of Birmingham, Birmingham, UK. 3. Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus, Aurora, CO, USA. 4. Division of Endocrinology, Ohio State University, Columbus, OH, USA. 5. Division of Diabetes and Endocrinology, Kobe University Hospital, Kobe, Japan. 6. Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellín, Colombia. 7. Pacific Neuroscience Institute & John Wayne Cancer Institute, Santa Monica, CA, USA. 8. Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Mail Code: CH8N, 3303 SW Bond Ave., Portland, OR, 97239, USA. fleseriu@ohsu.edu.
Abstract
PURPOSE: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. METHODS: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. RESULTS: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. CONCLUSIONS: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.
PURPOSE: In view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues. METHODS: The Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018. RESULTS: There is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function. CONCLUSIONS: International pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.
Authors: Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus Journal: Radiology Date: 2015-04-06 Impact factor: 11.105
Authors: Yuri Errante; Vincenzo Cirimele; Carlo Augusto Mallio; Vincenzo Di Lazzaro; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi Journal: Invest Radiol Date: 2014-10 Impact factor: 6.016
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Martin R Prince; Honglei Zhang; Michael Morris; Jennifer L MacGregor; Marc E Grossman; Jeffrey Silberzweig; Robert L DeLapaz; Henry J Lee; Cynthia M Magro; Anthony M Valeri Journal: Radiology Date: 2008-09 Impact factor: 11.105
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Alireza Ghajar; Pamela S Jones; Francisco J Guarda; Alex Faje; Nicholas A Tritos; Karen K Miller; Brooke Swearingen; Lisa B Nachtigall Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958
Authors: Eva C Coopmans; Mark R Postma; Thalijn L C Wolters; Sebastiaan W F van Meyel; Romana Netea-Maier; André P van Beek; Sebastian J C M M Neggers Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: David Netuka; Andre Grotenhuis; Nicolas Foroglou; Francesco Zenga; Sebastien Froehlich; Florian Ringel; Nicolas Sampron; Nick Thomas; Martin Komarc; Martin Majovsky Journal: Int J Endocrinol Date: 2022-04-11 Impact factor: 2.803